Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/dth.14328 http://scihub22266oqcxt.onion/10.1111/dth.14328 32986289!7536947!32986289     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32986289&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Dermatol+Ther 2021 ; 34 (1): e14328 Nephropedia Template TP {{tp|p=32986289|t=2021. Management of urticaria in COVID-19 patients: A systematic review |pdf=|usr=}}{{32986289}} gab.com Text Management of urticaria in COVID-19 patients: A systematic review JO: Dermatol Ther http://www.kidney.de/pget.php?&tw=1&pmid=32986289 #FOAvip The global pandemic COVID-19 has resulted in significant global morbidity, mortality and increased healthcare demands. There is now emerging evidence of patients experiencing urticaria. We sought to systematically review current evidence, critique the literature, and present our findings. Allowing PRISMA guidelines, a comprehensive literature search was carried out with Medline, EMBASE, Scopus, Cochrane, and Google Scholar, using key MeSH words, which include "COVID-19," "Coronavirus," "SARS-Cov-2," "Urticaria," "Angioedema," and "Skin rash" up to 01 August 2020. The key inclusion criteria were articles that reported on urticaria and/or angioedema due to COVID-19 infection and reported management and outcome. Studies were excluded if no case or cohort outcomes were observed. Our search returned 169 articles, 25 of which met inclusion criteria. All studies were case reports, reporting 26 patients with urticaria and/or angioedema, COVID-19 infection and their management and/or response. ajority of patients (n = 16, 69%) were over 50 years old. However, urticaria in the younger ages was not uncommon, with reported case of 2 months old infant. Skin lesions resolved from less than 24 hours to up to 2 weeks following treatment with antihistamines and/or steroids. There have been no cases of recurrent urticaria or cases nonresponsive to steroids. Management of urticarial in COVID-19 patients should involve antihistamines. Low dose prednisolone should be considered on an individualized basis. Further research is required in understanding urticarial pathogenesis in COVID-19. This will aid early diagnostic assessment in patients with high index of suspicion and subsequent management in the acute phase. Twit Text FOAVip Management of urticaria in COVID-19 patients: A systematic review ????Dermatol Ther http://www.kidney.de/pget.php?&tw=1&pmid=32986289 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32986289 #FOAvip English Wikipedia <ref>{{Cite pmid|32986289}}</ref> Management of urticaria in COVID-19 patients: A systematic review #MMPMID32986289 Abuelgasim E; Dona ACM; Sondh RS; Harky A Dermatol Ther 2021[Jan]; 34 (1): e14328 PMID32986289show ga The global pandemic COVID-19 has resulted in significant global morbidity, mortality and increased healthcare demands. There is now emerging evidence of patients experiencing urticaria. We sought to systematically review current evidence, critique the literature, and present our findings. Allowing PRISMA guidelines, a comprehensive literature search was carried out with Medline, EMBASE, Scopus, Cochrane, and Google Scholar, using key MeSH words, which include "COVID-19," "Coronavirus," "SARS-Cov-2," "Urticaria," "Angioedema," and "Skin rash" up to 01 August 2020. The key inclusion criteria were articles that reported on urticaria and/or angioedema due to COVID-19 infection and reported management and outcome. Studies were excluded if no case or cohort outcomes were observed. Our search returned 169 articles, 25 of which met inclusion criteria. All studies were case reports, reporting 26 patients with urticaria and/or angioedema, COVID-19 infection and their management and/or response. ajority of patients (n = 16, 69%) were over 50 years old. However, urticaria in the younger ages was not uncommon, with reported case of 2 months old infant. Skin lesions resolved from less than 24 hours to up to 2 weeks following treatment with antihistamines and/or steroids. There have been no cases of recurrent urticaria or cases nonresponsive to steroids. Management of urticarial in COVID-19 patients should involve antihistamines. Low dose prednisolone should be considered on an individualized basis. Further research is required in understanding urticarial pathogenesis in COVID-19. This will aid early diagnostic assessment in patients with high index of suspicion and subsequent management in the acute phase. |*COVID-19/complications[MESH] |*Urticaria/complications/diagnosis/drug therapy[MESH] |Humans[MESH] |Pandemics[MESH]Management of urticaria in COVID-19 patients: A systematic review (epmc).pdf DeepDyve Pubget Overpricing